阿德福韦在预防肝移植后乙肝复发中的应用

Role of adefovir in prevention of hepatitis B recurrence after liver transplantation

目的评价adefovir在预防肝移植后乙肝复发中的应用效果及安全性.方法统计30例应用lamivudine出现耐药及病毒变异的肝移植病例加用adefovir后病人：ALT、HBV-DNA、Cr以及HBeAg的变化,以及观察adefovir的副作用.结果应用adefovir12周后,ALT恢复正常者占65.5%,HBVDNA转阴（＜10^4拷贝/ml）占76.7%,HBeAg转阴44%,未发现严重的肾功能异常及其它副作用.结论肝移植术后应用lamivudine出现耐药及病毒变异病例,及时加用adefovir可有效改善肝功能、抑制肝炎复发.

Objective To determine the effectiveness and safety of adefovir in treatment of hepatitis B recurrence after liver transplantation. Methods After the liver transplantation, adefovir was administered to 30 lamivudine-resistant patients with viral mutation for 12 weeks. Then the changes in ALT, HBV-DNA, Cr and HBeAg were determined and the side effect of the drug observed. Results The ALT became normal in 65.5%, HBV-DNA was negative in 76.7% and HBeAg was negative in 44% of the patients. Meanwhile, no serious side effect of the drug was found. Conclusions Adefovir is an effective drug for treatment of hepatitis B recurrence after liver transplantation.